Viking Therapeutics (VKTX) Change in Accured Expenses (2016 - 2025)
Historic Change in Accured Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$4.8 million.
- Viking Therapeutics' Change in Accured Expenses fell 14257.09% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 million, marking a year-over-year decrease of 12124.73%. This contributed to the annual value of $5.8 million for FY2024, which is 42026.43% up from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Change in Accured Expenses is -$4.8 million, which was down 14257.09% from $14.6 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Change in Accured Expenses ranged from a high of $15.9 million in Q1 2024 and a low of -$13.6 million during Q2 2024
- Moreover, its 5-year median value for Change in Accured Expenses was -$22000.0 (2021), whereas its average is $705526.3.
- As far as peak fluctuations go, Viking Therapeutics' Change in Accured Expenses crashed by 86271.51% in 2023, and later soared by 647288.14% in 2024.
- Viking Therapeutics' Change in Accured Expenses (Quarter) stood at -$1.1 million in 2021, then skyrocketed by 330.71% to $2.5 million in 2022, then soared by 57.26% to $3.9 million in 2023, then plummeted by 299.8% to -$7.8 million in 2024, then soared by 38.72% to -$4.8 million in 2025.
- Its last three reported values are -$4.8 million in Q3 2025, $14.6 million for Q2 2025, and -$5.7 million during Q1 2025.